MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation DPO Ratio 2011-2026 | ADMP
Annual DPO Ratio Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 345 | 192 | 85.6 | 101 | 155 | 144 | 162 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 | 85.6 | 169 |
Quarterly DPO Ratio Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.66 K | 452 | - | 272 | 623 | 270 | - | 159 | 179 | 144 | - | 170 | 68 | 96 | - | 97.6 | 106 | 106 | - | 165 | 159 | 157 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.66 K | 68 | 346 |
DPO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
38 | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
309 | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
116 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
352 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-807 | $ 3.28 | -0.88 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
33.4 | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
41.8 | - | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
37.3 | $ 22.79 | 0.6 % | $ 1.05 B | USA |
 |
Athenex
ATNX
|
111 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
224 | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
212 | $ 2.52 | - | $ 1.33 B | Canada |
 |
DURECT Corporation
DRRX
|
519 | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
55.8 | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
39.3 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
5.36 K | - | - | $ 36.6 M | USA |
 |
Rockwell Medical
RMTI
|
20.9 | $ 1.03 | 1.47 % | $ 24 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
775 | $ 3.17 | 3.93 % | $ 44.6 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
32.3 | $ 2.36 | -7.45 % | $ 2.93 M | USA |
 |
Bausch Health Companies
BHC
|
78.1 | $ 4.96 | -2.84 % | $ 1.81 B | Canada |
 |
Harrow Health
HROW
|
199 | $ 35.07 | 3.15 % | $ 1.29 B | USA |
 |
OptiNose
OPTN
|
194 | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
53 | $ 6.49 | 0.62 % | $ 4.01 B | Canada |
 |
Evolus
EOLS
|
59.4 | $ 4.42 | -5.6 % | $ 285 M | USA |
 |
Veru
VERU
|
264 | $ 2.28 | -0.87 % | $ 308 M | USA |
 |
Viatris
VTRS
|
64 | $ 13.41 | 0.9 % | $ 16.1 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
75.6 | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
54.2 | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
45.4 | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
215 | - | - | $ 33.6 M | USA |
 |
TherapeuticsMD
TXMD
|
723 | $ 2.34 | 1.3 % | $ 24.4 M | USA |
 |
Radius Health
RDUS
|
274 | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
36.8 | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
84 | $ 0.78 | 2.71 % | $ 3.36 M | USA |
 |
SCYNEXIS
SCYX
|
20.2 | $ 0.87 | -0.32 % | $ 43.4 M | USA |
 |
Organogenesis Holdings
ORGO
|
94 | $ 2.4 | -2.63 % | $ 316 M | USA |
 |
Perrigo Company plc
PRGO
|
64.2 | $ 9.6 | 0.31 % | $ 1.33 B | USA |
 |
Canopy Growth Corporation
CGC
|
52.8 | $ 0.94 | -3.2 % | $ 101 M | Canada |
 |
Assertio Holdings
ASRT
|
122 | $ 16.0 | 14.29 % | $ 102 M | USA |
 |
Recro Pharma
REPH
|
6.63 | - | -4.76 % | $ 65.3 M | USA |